$CYCC
Cyclacel Pharmaceuticals, Inc.

2023 Q3 Form 10-Q Financial Statement

#000155837023014533 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $16.00K $373.0K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.625M $1.575M
YoY Change -20.89% -0.32%
% of Gross Profit
Research & Development $5.236M $4.727M
YoY Change 18.65% 12.41%
% of Gross Profit
Depreciation & Amortization $3.000K $8.000K
YoY Change -57.14% 0.0%
% of Gross Profit
Operating Expenses $6.861M $6.302M
YoY Change 6.09% 8.94%
Operating Profit -$6.845M -$5.929M
YoY Change 5.85% 2.49%
Interest Expense $154.0K $1.000K
YoY Change -55.1% -99.56%
% of Operating Profit
Other Income/Expense, Net $145.0K -$105.0K
YoY Change -59.38% -146.46%
Pretax Income -$6.700M -$6.034M
YoY Change 9.66% 8.54%
Income Tax -$668.0K -$586.0K
% Of Pretax Income
Net Earnings -$6.032M -$5.448M
YoY Change 18.37% 19.08%
Net Earnings / Revenue -37700.0% -1460.59%
Basic Earnings Per Share -$0.44
Diluted Earnings Per Share -$7.20 -$0.44
COMMON SHARES
Basic Shares Outstanding 12.64M 12.54M
Diluted Shares Outstanding 12.55M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.944M $10.16M
YoY Change -74.93% -65.04%
Cash & Equivalents $5.900M $10.20M
Short-Term Investments
Other Short-Term Assets $1.950M $2.186M
YoY Change 1047.06% 2667.09%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $11.11M $15.29M
YoY Change -60.19% -52.32%
LONG-TERM ASSETS
Property, Plant & Equipment $16.00K $24.00K
YoY Change -56.76% -50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.259M $1.000M
YoY Change -56.82% -67.32%
Total Long-Term Assets $1.384M $1.148M
YoY Change -55.44% -64.88%
TOTAL ASSETS
Total Short-Term Assets $11.11M $15.29M
Total Long-Term Assets $1.384M $1.148M
Total Assets $12.50M $16.44M
YoY Change -59.71% -53.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.571M $2.169M
YoY Change 59.82% -1.63%
Accrued Expenses $6.577M $4.577M
YoY Change 95.16% 62.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.148M $6.746M
YoY Change 87.18% 34.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $52.00K $66.00K
YoY Change -51.4% -41.59%
Total Long-Term Liabilities $52.00K $66.00K
YoY Change -51.4% -41.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.148M $6.746M
Total Long-Term Liabilities $52.00K $66.00K
Total Liabilities $8.200M $6.812M
YoY Change 83.86% 32.55%
SHAREHOLDERS EQUITY
Retained Earnings -$423.0M -$417.4M
YoY Change 6.09% 6.04%
Common Stock $12.00K $9.000K
YoY Change 33.33% -18.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.297M $5.136M
YoY Change
Total Liabilities & Shareholders Equity $12.50M $16.44M
YoY Change -59.71% -53.48%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$6.032M -$5.448M
YoY Change 18.37% 19.08%
Depreciation, Depletion And Amortization $3.000K $8.000K
YoY Change -57.14% 0.0%
Cash From Operating Activities -$4.032M -$1.305M
YoY Change -42.14% -31.85%
INVESTING ACTIVITIES
Capital Expenditures -$4.000K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $4.000K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -51.00K -51.00K
YoY Change -103.33% -103.46%
NET CHANGE
Cash From Operating Activities -4.032M -1.305M
Cash From Investing Activities 4.000K 0.000
Cash From Financing Activities -51.00K -51.00K
Net Change In Cash -4.079M -1.356M
YoY Change -24.96% 205.41%
FREE CASH FLOW
Cash From Operating Activities -$4.032M -$1.305M
Capital Expenditures -$4.000K $0.00
Free Cash Flow -$4.028M -$1.305M
YoY Change -42.19% -31.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12551794
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10136089
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12545526
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10065007
dei Entity Registrant Name
EntityRegistrantName
Cyclacel Pharmaceuticals, Inc.
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12539189
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12642822
dei Entity Central Index Key
EntityCentralIndexKey
0001130166
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
3117100
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
3117100
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-50626
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1707622
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Connell Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1500
dei Entity Address City Or Town
EntityAddressCityOrTown
Berkeley Heights
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07922
dei City Area Code
CityAreaCode
908
dei Local Phone Number
LocalPhoneNumber
517-7330
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12642822
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10164000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18345000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5130000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6066000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
15294000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
24411000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
124000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
142000
CY2023Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1000000
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2916000
CY2023Q2 us-gaap Assets
Assets
16442000
CY2022Q4 us-gaap Assets
Assets
27501000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2169000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2561000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4577000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4831000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6746000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7392000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
66000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
106000
CY2023Q2 us-gaap Liabilities
Liabilities
6812000
CY2022Q4 us-gaap Liabilities
Liabilities
7498000
CY2023Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
3117100
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
3117100
CY2023Q2 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
4494000
CY2022Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
4494000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12642822
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12539189
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
9000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
9000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
423633000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
422973000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1097000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1316000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-417409000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-406157000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
5136000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15509000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16442000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27501000
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
373000
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
373000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4727000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4205000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10401000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9159000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1575000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1580000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3220000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3185000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
6302000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
5785000
us-gaap Operating Expenses
OperatingExpenses
13621000
us-gaap Operating Expenses
OperatingExpenses
12344000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5929000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5785000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13248000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12344000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-76000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
209000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-161000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
238000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
77000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
17000
us-gaap Investment Income Interest
InvestmentIncomeInterest
193000
us-gaap Investment Income Interest
InvestmentIncomeInterest
21000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-106000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
58000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1280000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-105000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
226000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
90000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1539000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6034000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5559000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13158000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10805000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-586000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-984000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1906000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2122000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5448000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4575000
us-gaap Net Income Loss
NetIncomeLoss
-11252000
us-gaap Net Income Loss
NetIncomeLoss
-8683000
CY2023Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
50000
CY2022Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
50000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
101000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
101000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5498000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4625000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11353000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8784000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12551794
us-gaap Net Income Loss
NetIncomeLoss
-8683000
us-gaap Depreciation
Depreciation
16000
us-gaap Depreciation
Depreciation
17000
us-gaap Share Based Compensation
ShareBasedCompensation
760000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10136089
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12545526
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10065007
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5448000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4575000
us-gaap Net Income Loss
NetIncomeLoss
-11252000
us-gaap Net Income Loss
NetIncomeLoss
-8683000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5450000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
15715000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-10621000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
21518000
CY2023Q2 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
5577000
CY2022Q2 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-16168000
cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
10840000
cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-22046000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5321000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5028000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11033000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9211000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
37263000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
380000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
50000
CY2022Q1 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-5878000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5803000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4108000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
33410000
CY2022Q2 cycc Stock Issued During Period Value At Market Issuance Sales Agreement
StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement
1525000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
350000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
50000
CY2022Q2 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-16168000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
15715000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4575000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
30207000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15509000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
401000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
50000
CY2023Q1 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
5263000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5171000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5804000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
10148000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
359000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
50000
CY2023Q2 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
5577000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5450000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5448000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
5136000
us-gaap Net Income Loss
NetIncomeLoss
-11252000
us-gaap Share Based Compensation
ShareBasedCompensation
730000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-40000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3289000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
926000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-939000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
172000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8166000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8690000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7000
cycc Proceeds From Issuance Of Common Stock And Warrant Exercises Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantExercisesNetOfIssuanceCosts
0
cycc Proceeds From Issuance Of Common Stock And Warrant Exercises Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantExercisesNetOfIssuanceCosts
1525000
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
101000
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
101000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-101000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1424000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
92000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-209000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8181000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7482000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18345000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36559000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10164000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29077000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
193000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
21000
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
4846000
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
3328000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2000
cycc Accrual Of Preferred Stock Dividends
AccrualOfPreferredStockDividends
50000
cycc Accrual Of Preferred Stock Dividends
AccrualOfPreferredStockDividends
50000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10200000
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6178034
CY2022Q4 cycc Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3611000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
248000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
333000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
234000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
887000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4577000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4831000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
373000
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
373000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7147106
CY2023Q2 us-gaap Deferred Income Taxes And Other Tax Receivable Current
DeferredIncomeTaxesAndOtherTaxReceivableCurrent
1953000
CY2022Q4 us-gaap Deferred Income Taxes And Other Tax Receivable Current
DeferredIncomeTaxesAndOtherTaxReceivableCurrent
4664000
CY2023Q2 cycc Prepayments And Value Added Tax Receivable Current
PrepaymentsAndValueAddedTaxReceivableCurrent
991000
CY2022Q4 cycc Prepayments And Value Added Tax Receivable Current
PrepaymentsAndValueAddedTaxReceivableCurrent
976000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
2186000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
426000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5130000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6066000
CY2023Q2 cycc Deposits Held By Related Party Current
DepositsHeldByRelatedPartyCurrent
1500000
CY2023Q2 cycc Deposits Held By Related Party
DepositsHeldByRelatedParty
1000000.0
CY2023Q2 cycc Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
4095000
us-gaap Operating Lease Expense
OperatingLeaseExpense
36949
us-gaap Operating Lease Expense
OperatingLeaseExpense
30470
us-gaap Operating Lease Payments
OperatingLeasePayments
36318
us-gaap Operating Lease Payments
OperatingLeasePayments
30870
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
38000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
66000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
38000
CY2023Q2 cycc Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
0
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
142000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
359000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
350000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
760000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
731000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0

Files In Submission

Name View Source Status
0001558370-23-014533-index-headers.html Edgar Link pending
0001558370-23-014533-index.html Edgar Link pending
0001558370-23-014533.txt Edgar Link pending
0001558370-23-014533-xbrl.zip Edgar Link pending
cycc-20230630.xsd Edgar Link pending
cycc-20230630x10q.htm Edgar Link pending
cycc-20230630xex31d1.htm Edgar Link pending
cycc-20230630xex31d2.htm Edgar Link pending
cycc-20230630xex32d1.htm Edgar Link pending
cycc-20230630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
cycc-20230630_cal.xml Edgar Link unprocessable
cycc-20230630_def.xml Edgar Link unprocessable
cycc-20230630_lab.xml Edgar Link unprocessable
cycc-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cycc-20230630x10q_htm.xml Edgar Link completed
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending